Last update 23 Dec 2024
ONO-4578
Last update 23 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms BMS-986310, BMS986310, ONO 4578 + [1] |
Target |
Mechanism EP4 antagonists(Prostanoid EP4 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
13
Clinical Trials associated with ONO-4578A Randomized, Multicenter, Double-blind, Phase II Study to Compare the Efficacy and Safety of the Treatment With ONO-4578 in Combination With Nivolumab, Fluoropyrimidine-based and Platinum- Based Chemotherapy (Hereinafter Referred to as Chemotherapy) With Those of the Treatment With Placebo in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
ONO-4578-06: Phace I , Open-label, non-blind, first-line endocrine therapy with ONO-4578 and standard treatment letrozole and CDK4 /6 inhibitors (palbociclib or abemaciclib) in patients with metastatic or recurrent postmenopausal hormone receptor-positive HER2-negative breast cancer
ONO-4578-06: Phase I , Open-label, Non-blind, First-line Endocrine Therapy With ONO-4578 and Standard Treatment Letrozole and CDK4/6 Inhibitors (Palbociclib or Abemaciclib) in Patients With Metastatic or Recurrent Postmenopausal Hormone Receptor-positive HER2-negative Breast Cancer
100 Clinical Results associated with ONO-4578
Login to view more data
100 Translational Medicine associated with ONO-4578
Login to view more data
100 Patents (Medical) associated with ONO-4578
Login to view more data
100 Deals associated with ONO-4578
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Gastrooesophageal junction cancer | Phase 2 | JP | 06 Dec 2023 | |
| Gastrooesophageal junction cancer | Phase 2 | KR | 06 Dec 2023 | |
| Gastrooesophageal junction cancer | Phase 2 | TW | 06 Dec 2023 | |
| HER2 negative Gastric Cancer | Phase 2 | JP | 06 Dec 2023 | |
| HER2 negative Gastric Cancer | Phase 2 | KR | 06 Dec 2023 | |
| HER2 negative Gastric Cancer | Phase 2 | TW | 06 Dec 2023 | |
| Breast cancer recurrent | Phase 1 | JP | 09 Nov 2021 | |
| HER2-negative breast cancer | Phase 1 | JP | 09 Nov 2021 | |
| Hormone receptor positive breast cancer | Phase 1 | JP | 09 Nov 2021 | |
| Hormone receptor positive HER2 negative breast cancer | Phase 1 | JP | 09 Nov 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | Metastatic Colorectal Carcinoma Proficient DNA Mismatch Repair (pMMR) | Microsatellite Stable (MSS) | 34 | fpxjguzwdw(nsiqxgpjly) = 28 (82.4%) with grade ≥3 and 20 (58.8%) with serious TEAEs; 15 patients (44.1%) discontinued of any study treatment due to TEAEs. No patient died due to TEAEs ihmoxnryqq (kvdfjffabh ) | Positive | 30 Jun 2024 | ||
Phase 1 | 31 | lilzzvqqib(yfpkzcdirw) = thhjeahocq wlkkhqxjsf (valvqzlrhl ) | Positive | 09 Sep 2022 | |||
tqdjvrvija(ylwyyyzeig) = xdhyxvnnns urxadmeuel (cfqncnddkv ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free